Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 247

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 247
---
 completion of the Pre -INDdiscussions with the US FDA. The Pre -INDdiscussions focused on overall development plan in preparation for the IND application of ALS -4targeting Acute Bacterial Skin and Skin Structure Infections (ABSSSI) initially. With the positive feedback on the overall development strategy from the US FDA, we are proceeding towards the IND submission of ALS -4seeking to initiate a Phase 2 clinical study to assess the efficacy of ALS -4in patients. The timing and scope of advancing ALS -4Phase 2 clinical trials will be contingent upon securing appropriate collaborative partnerships and adequate funding resources. The Company is actively seeking strategic collaborators who can provide both financial support and clinical expertise to advance these Phase 2 clinical trials. Patent License On October 18, 2017, the Company’s subsidiary, Acticule, entered into an exclusive license agreement with Versitech Limited, the licensing entity of HKU, for ALS -4. Subsequently on June 7, 2018, the parties entered into a first amendment to the exclusive license agreement, and on July 10, 2019, the parties entered into a second amendment to the license agreement. On January 11, 2019, Acticule and Versitech Limited entered into a second license agreement for ALS -4, where Acticule exclusively licensed the intellectual property rights on certain HKU -ownedimprovements to the original licensed invention. Under the exclusive license agreements, we were granted an exclusive, royalty -bearing, sublicensable licenses to develop, make, have made, use, sell, offer for sale and import products that are covered by the licensed patents (as described below). The territory of the licenses is worldwide and the field of the licenses is for treatment or prevention of bacterial infections caused by Staphylococcus aureus including MRSA and bacterial virulence. We paid an upfront fee upon entering into the license agreements. We are required to pay less than 10% of the net sales of the licensed products sold by us or our affiliates as royalties, as well as a low teens percentage of sublicense royalties that we receive from our sublicensees, if any. In addition, we agreed to pay to the licensor aggregate regulatory milestones of up to US$1 million subject to the following achievements: submission of investigational new drug application; completion of phase1, 2 and 3 clinical trials; and submission of new drug application; grant of regulatory approval. We also agreed to pay to the licensor aggregate sales milestones